Two Sigma Advisers
PHAT icon

Two Sigma Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

Two Sigma Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-133,700
Closed -$1.09M – 2537
2024
Q4 		$1.09M Buy
+133,700
New +$1.66M ﹤0.01% 1416
2024
Q3 		– Sell
-16,300
Closed -$168K – 2464
2024
Q2 		$168K Sell
16,300
-35,300
-68% -$364K ﹤0.01% 2247
2024
Q1 		$548K Buy
51,600
+28,900
+127% +$245K ﹤0.01% 1835
2023
Q4 		$207K Buy
+22,700
New +$196K ﹤0.01% 2220
2023
Q1 		– Sell
-14,800
Closed -$166K – 2721
2022
Q4 		$166K Sell
14,800
-9,300
-39% -$95.9K ﹤0.01% 2222
2022
Q3 		$267K Sell
24,100
-8,800
-27% -$83.8K ﹤0.01% 2098
2022
Q2 		$278K Sell
32,900
-5,100
-13% -$52.4K ﹤0.01% 2146
2022
Q1 		$517K Buy
38,000
+5,900
+18% +$95.3K ﹤0.01% 1972
2021
Q4 		$631K Buy
32,100
+15,700
+96% +$369K ﹤0.01% 1799
2021
Q3 		$526K Sell
16,400
-9,100
-36% -$302K ﹤0.01% 1910
2021
Q2 		$863K Sell
25,500
-5,900
-19% -$211K ﹤0.01% 1698
2021
Q1 		$1.18M Buy
+31,400
New +$1.31M ﹤0.01% 1565

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Two Sigma Advisers's PHAT Position: Q1 2025 in Review

Two Sigma Advisers sold out of Phathom Pharmaceuticals (PHAT) in Q1 2025, closing a stake of 133,700 shares — an estimated $1.09M sold.

Two Sigma Advisers first reported a position in PHAT in Q1 2021 and held it in 12 quarters. The position peaked at $1.18M in Q1 2021. 137 funds tracked by Wall St. Rank hold PHAT as of Q1 2025.

  • Two Sigma Advisers reported no remaining Phathom Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 133,700 Phathom Pharmaceuticals shares in Q1 2025, an estimated $1.09M.
  • Two Sigma Advisers first reported a position in Phathom Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Two Sigma Advisers's Phathom Pharmaceuticals position peaked at $1.18M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.